English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 1/5 criteria met.
- ❌ Price trend failed
- ❌ Growth failed
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2021 → 2022: -70.01%
Price change 2022 → 2023: 51.55%
Price change 2023 → 2024: -70.07%
Price change 2024 → 2025: 199.09%
Price change 2025 → 2026: -38.75%
Price change 2026 (year to date): -39.12%
Financial growth
Revenue CAGR (7 years): -100.00%
Earnings CAGR (7 years): N/A
Growth status: insufficient data or negative trend.
Debt
Debt-to-equity ratio: 0.02
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -3.91
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 34.26% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="IMRX" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| Immuneering Corporation | – | 0.02 | – | 🔒 |
| Valerio Therapeutics S.A. | – | 3.67 | −13.5 % | – |
| Transgene S.A. | – | 0.02 | −20.1 % | – |
| LNA Santé S.A. | 9.7 | 2.75 | +10.4 % | – |
| Eurobio Scientific S.A. | 36.8 | 0.09 | +22.1 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by Immuneering Corporation over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2019 | 1.9 m | -7.7 m | -401.6 % | n/a |
| 2020 | 2.3 m | -17.0 m | -737.2 % | +20.4 % |
| 2021 | 2.1 m | -33.5 m | -1,612.3 % | -10.0 % |
| 2022 | 316,952 | -50.5 m | -15,937.3 % | -84.8 % |
Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.
Accounts and financial health
Balance sheet and cash flow published by Immuneering Corporation over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 149 m | 106 m | 85.7 m | 36.1 m | 173 m |
| Total Debt | 5.4 m | 4.8 m | 4.5 m | 4.2 m | 3.8 m |
| Net Debt | -69.5 m | -67.8 m | -54.9 m | -32.0 m | -125 m |
| Equity | 156 m | 110 m | 90.6 m | 41.4 m | 218 m |
| Total assets | 167 m | 122 m | 103 m | 52.7 m | 232 m |
| Operating cash flow | -30.9 m | -44.1 m | -49.0 m | -55.0 m | -45.3 m |
| Investments (capex) | 60,786 | 742,483 | 342,746 | 84,875 | 142,226 |
| Free cash-flow | -30.9 m | -44.8 m | -49.3 m | -55.1 m | -45.5 m |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Analyst consensus and forecasts
What the financial analysts covering Immuneering Corporation publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Price targets: published for companies listed in the United States only.
Track record against expectations: reported EPS above consensus 4 times over the last 12 releases.
Source: ratings and forecasts published by analysts, collected on 07/11/2026. An analyst rating or target is not a guarantee.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about Immuneering Corporation
What is the Immuneering Corporation share price?
Latest recorded price: 3.68 USD on 06/11/2026, for a market cap of 238 m USD.
What is the revenue of Immuneering Corporation?
316,952 USD for fiscal year 2022, with net income of -50.5 m USD (net margin -15,937.3 %).
What do analysts say about Immuneering Corporation?
Out of 11 analysts: 7 buy or strong buy, 4 hold, 0 sell or strong sell.
Is Immuneering Corporation stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US45254E1073).
How many employees does Immuneering Corporation have?
54 full-time employees according to the latest published profile.
Who runs Immuneering Corporation?
Benjamin J. Zeskind is the company's chief executive.